What is Non-IgG Antibody Drug Conjugate
Non-IgG Antibody Drug Conjugate (non-IgG ADC) is a novel drug combination that combines antibodies specifically targeting specific proteins or cell surface markers with potent cytotoxic drugs, thus providing highly targeted and effective treatments for certain cancers. Traditionally, ADCs have been designed using immunoglobulin G (IgG) antibodies, the most abundant type of antibody in the human immune system. Different from traditional ADC technology, non-IgG ADCs uses non-IgG antibodies (such as IgA, IgE, IgM) to bind to receptors on the cell surface. Once the antibody binds to the receptor, the drug will be released into the tumor cells, so as to achieve the therapeutic purpose of precisely targeting tumors.
Advantages of non-IgG ADCs
Although the efficacy of IgG ADCs has been demonstrated, non-IgG antibodies such as IgA, IgE, and IgM have different structural and functional properties, as well as broader lymphatic and intracellular penetration capabilities, which may provide unique advantages in terms of ADC design and performance. For example:
- Smaller drug molecules: Non-IgG antibody-drug conjugates have smaller molecules, with a molecular weight of 1/4 to 1/2 of IgG, so they can enter the tissue cell space faster, thereby improving the tissue permeability and diffusion of drugs sex. This helps the drug to accumulate a higher drug concentration locally in the tumor and achieve better efficacy.
- Lower immunogenicity: Traditional IgG ADCs usually use large antibodies as drug carriers, which may cause immunogenic reactions. Non-IgG ADCs use smaller proteins as drug carriers and are generally less immunogenic, reducing potential immune responses.
- Higher targeting diversity: non-IgG ADCs can use multiple types of antibodies as drug carriers, which allows greater flexibility in targeting diversity. This means that vectors that are more suitable for specific tumor types or treatment strategies can be selected, thereby improving the precision and efficacy of treatment.
- Shorter serum half-life: The serum half-life of non-IgG antibody-drug conjugates is shorter than that of IgG antibody-drug conjugates, which can reduce the circulation time of drugs in the blood and reduce unnecessary side effects.
- Diversity of possible pathways: Non-IgG ADCs can usually release drugs through different intracellular pathways, thus providing a diversity of therapeutic mechanisms. This can not only increase the killing effect of drugs on tumor cells, but also effectively deal with the problem of drug resistance.
In short, non-IgG ADC is not your average oncology therapy; it is a new kid on the block, still in the early research and development stage. However, it is clear that this new field has crazy potential and might be a game changer for future oncology therapies. Creative Biolabs has over 10 years of core experience in bioconjugation chemistry and antibody development to bring you best-in-class, next-generation non-IgG antibody-drug conjugate services. Please click on the Online Inquiry to learn more and let's make some miracles together!
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.